<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671188</url>
  </required_header>
  <id_info>
    <org_study_id>200928</org_study_id>
    <nct_id>NCT02671188</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis</brief_title>
  <official_title>A Multi-centre, Randomised, Double-blind (Sponsor Open), Placebo-controlled, Repeat Dose, Proof of Mechanism Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemokine (C-C motif) ligand 20 (CCL20) is a protein involved in attracting immune cells
      including subsets of T cells (for example Th17 cells), B cells, natural killer cells and
      dendritic cells to inflamed tissues in conditions such as psoriasis (Ps) and psoriatic
      arthritis (PsA). CCL20 acts by binding and activating the chemokine receptor 6 (CCR6) present
      on the surface of the inflammatory cells. Levels of CCL20 are increased in inflamed tissues
      in psoriasis (Ps) and inflammatory arthritis. GSK3050002 is a humanized Immunoglobulin G
      (Ig)G monoclonal antibody, which binds to and neutralizes the action of human CCL20. The
      hypothesis is that GSK3050002 will reduce the movement of inflammatory cells into tissues
      affected by Ps or PsA, thereby leading to an improvement in disease activity. The primary
      objective of this multi-centre, randomized, double-blind (sponsor open), placebo-controlled
      trial is to evaluate the safety and tolerability of repeat doses of GSK3050002, and to
      understand the mechanism of action (by taking skin and synovial biopsy samples) and potential
      for clinical efficacy of GSK3050002 in subjects with PsA. A minimum of 18 subjects and up to
      a maximum of 30 subjects will be randomised into the study to either GSK3050002 or placebo in
      a 2:1 ratio to ensure that approximately 18 evaluable subjects complete the study. The total
      duration of participation in the study will be approximately 21 weeks from screening to last
      study visit.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">August 9, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events (AE)</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Serious Adverse Events</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the subjects or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with drug-induced liver injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of clinical laboratory assessments as a measure of safety and tolerability.</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>Clinical laboratory assessments will include hematology, clinical chemistry and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of vital signs as a measure of safety and tolerability.</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>Vital signs to be measured in semi-supine position after at least 5 minutes rest and will include temperature, systolic and diastolic blood pressure, and pulse rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) assessment as a measure of safety and tolerability.</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>A single 12-lead ECG will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK3050002- CCL20 complex levels in serum</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>Blood samples will be collected on baseline (Day-10 to -1), at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on D 15 and D 29, D 43, D 85, D 113 +/- 3 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of CD3+ T cells synovial tissue and skin biopsy in samples</measure>
    <time_frame>Baseline and Day 43</time_frame>
    <description>Synovial and skin lesion biopsy tissue will be collected and evaluated for general appearance and inflammatory infiltrate including CD3+ T-cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Score 28 (DAS28)</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>DAS28 is a composite arthritis disease activity index comprising swollen and tender joint count (28 joints), patient global assessment of disease activity, and C-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in American College of Rheumatology (ACR) responders</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>ACR is a composite score of the patient assessment of joint pain, the patient global assessment of disease activity, the physician global assessment of disease activity, the 66/68 swollen/tender joint count, the Disability Index of the Health Assessment Questionnaire (HAQ-DI) questionnaire, and C-reactive protein. The ACR is reported as % improvement (20%, 50% or 70%), between two discrete timepoints, as calculated by improvement in the 66/68 swollen/tender joint count, and improvement in at least three of the remaining five composite parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>PASDAS is a composite disease activity index for psoriatic arthropathies comprising the 66/68 swollen/tender joint count, patient global assessment of disease activity, physician global assesment of disease activity, Leeds enthesitis index, dactylitis score, SF-36 questionnaire and C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Psoriasis Lesion Severity Score (PLSS)</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>The PLSS is the sum of the erythema, scaling and plaque thickness scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>The PASI scoring system is a widely-used standard clinical tool for assessing the severity of psoriasis that takes into account the overall severity of erythema (redness), thickness (induration), and scale, as well as the extent of body surface area (BSA) affected with psoriasis. Higher scores indicate more severe disease. PASI is a static measurement made without reference to previous scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of serum anti- GSK3050002 antibody levels</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>Serum samples will be collected from all subjects at pre-dose and various time points post-dosing. An assay for detecting Anti-drug Antibodies (ADAs) against GSK3050002 will be done using validated electrochemiluminescent (ECL) bridging assay and the Meso-Scale Discovery (MSD) technology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titres of serum anti- GSK3050002 antibody levels</measure>
    <time_frame>Baseline and Up to Day 116</time_frame>
    <description>The serum which contain potential anti-GSK3050002 antibodies will be confirmed by immunocompetition using excess drug. Confirmed samples with ADA will be further analyzed for titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentrations (Cmax) after repeat dosing of GSK3050002</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve over the dosing interval AUC (0- tau) after repeat dosing of GSK3050002</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL) after repeat dosing of GSK3050002</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V) after repeat dosing of GSK3050002</measure>
    <time_frame>Up to Day 116</time_frame>
    <description>Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>GSK3050002 100 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3050002</intervention_name>
    <description>The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.</description>
    <arm_group_label>GSK3050002 100 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline (0.9% sodium chloride) will be used as placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;=18 years and &lt;=75 years of age at the time of consent.

          -  Diagnosis of, and currently active psoriatic arthritis with &gt;=3 tender and &gt;=3 swollen
             joints, one of which must be either a knee or ankle joint suitable for synovial
             biopsies.

          -  C-reactive protein (CRP) &gt;=3mg/l at the time of screening, thought by the investigator
             to be due to active PsA.

          -  A negative test result for Rheumatoid Factor at screening.

          -  Active PsA despite an adequate course of treatment with at least one of the following
             Disease-modifying anti-rheumatic drugs (DMARDS): methotrexate, sulfasalazine or
             leflunomide for a minimum of 3 months, with a stable dose prior to screening. The
             subject may have received prior treatment for their PsA with up to three oral DMARDS.

          -  At least 2 active psoriatic skin lesions &gt;=3centimetre (cm) x 3cm diameter at the time
             of the screening visit which in the opinion of the investigator will still be present
             in the Pre- Treatment Phase. Each plaque should have a total PLSS of &gt;=5, including an
             induration score of &gt;=2 (moderate or above) and a score of &gt;=1 in erythema and
             scaling. The PLSS is the sum of the erythema, scaling and induration scores. The skin
             lesions should be located in areas usually shielded from natural light by clothing
             (e.g. trunk or proximal extremities) and should not include scalp, inguinal or genital
             lesions.

          -  BMI within the range 18 - 35 kilogram per squared meter (kg/m^2) (inclusive).

          -  Female subjects are eligible to participate if they are not pregnant (as confirmed by
             a negative urine human chorionic gonadotrophin [hCG] test), not lactating, and at
             least one of the following conditions applies: 1. Pre-menopausal females with one of
             the following: a. Documented tubal ligation; b. Documented hysteroscopic tubal
             occlusion procedure with follow-up confirmation of bilateral tubal occlusion; c.
             Hysterectomy; d. Documented Bilateral Oophorectomy; e. Reproductive potential and
             agrees to follow one of the options listed below in the GSK (GlaxoSmithKline) Modified
             List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive
             Potential (FRP) requirements from 30 days prior to the first dose of study medication
             and until 12 weeks after the last dose of study medication and completion of the
             follow-up visit at Day 113.

             2. Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable
             cases a blood sample with simultaneous follicle stimulating hormone [FSH] and
             estradiol levels consistent with menopause [refer to laboratory reference ranges for
             confirmatory levels]). Females on hormone replacement therapy (HRT) and whose
             menopausal status is in doubt will be required to use one of the highly effective
             contraception methods if they wish to continue their HRT during the study. Otherwise,
             they must discontinue HRT to allow confirmation of post-menopausal status prior to
             study enrolment.

          -  Male subjects with female partners of child bearing potential must comply with the
             following contraception requirements from the time of first dose of study medication
             until 12 weeks after the last dose of study medication:Vasectomy with documentation of
             azoospermia; Male condom plus female partner use of one of the GSK Modified List of
             Highly Effective Methods for Avoiding Pregnancy in Females of Childbearing potential
             listed below. GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in
             Females of Reproductive Potential (FRP) does not apply to FRP with same sex partners,
             when this is their preferred and usual lifestyle or for subjects who are and will
             continue to be abstinent from penilevaginal intercourse on a long term and persistent
             basis. a. Contraceptive subdermal implant effectiveness criteria including a &lt;1% rate
             of failure per year, as stated in the product label. b. Intrauterine device or
             intrauterine system that meets effectiveness criteria including a &lt;1% rate of failure
             per year, as stated in the product label c. Oral Contraceptive, either combined or
             progestogen alone d. Injectable progestogen e. Contraceptive vaginal ring f.
             Percutaneous contraceptive patches g.Male partner sterilization with documentation of
             azoospermia prior to the female subject's entry into the study, and this male is the
             sole partner for that subject.

          -  Capable of giving signed informed consent which includes compliance with study
             procedures and requirements as listed in the consent form and in this protocol

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Planned surgical joint procedure, including intra-articular, tendon sheath, or bursal
             corticosteroid injections, during the study.

          -  Intra-articular corticosteroid injection, arthrocentesis or synovial biopsy on the
             joint that has been identified for biopsy or Magnetic resonance imaging (MRI) within 6
             weeks of the Pre-Treatment biopsy and MRI.

          -  Has undergone surgery, including synovectomy or arthroplasty, on the joint chosen for
             biopsy or MRI.

          -  History of joint disease, other than PsA, at the knee or ankle joint chosen for biopsy
             and/or MRI (eg gout, pseudogout, osteoarthritis).

          -  Diagnosed with a major chronic inflammatory or connective tissue disease other than Ps
             and PsA (e.g. rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis,
             ankylosing spondylitis).

          -  An active infection, or a history of infections as follows: a. A serious infection,
             defined as requiring hospitalization or intravenous antiinfectives within 8 weeks
             prior to Day 1. b. Oral anti-microbials within 14 days of Day 1. c. A history of
             opportunistic infections within 1 year of screening (e.g. pneumocystis jirovecii,
             cytomegalovirus pnemonitis, aspergillosis). This does not include infections that may
             occur in immunocompetent individuals, such as fungal nail infections or vaginal
             candidiasis, unless it is of an unusual severity or recurrent nature d.Recurrent or
             chronic infection or other active infection that, in the opinion of the investigator
             might cause this study to be detrimental to the subject e. History of Tuberculosis
             (TB), irrespective of treatment status f. A positive diagnostic TB test at screening
             defined as a positive QuantiFERONÂ®-TBGold (Registered product of QFT-G; Cellestis
             Ltd., Carnegie, Australia) test or T-spot test. In cases where the QuantiFERON or
             T-spot test is indeterminate, the subject may have the test repeated once, but they
             will not be eligible for the study unless the second test is negative, or they have a
             negative Tuberculin Purified Protein Derivative (PPD) skin test. A positive PPD
             (Mantoux) test is defined as &gt;=5mm of induration (size of raised lump not redness).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Known bleeding or coagulation disorder.

          -  Alanine aminotransferase (ALT) and bilirubin &gt;1.5x Upper Limit of Normal (ULN)
             (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct
             bilirubin &lt;35%).

          -  QT interval corrected (QTc) &gt; 450 milliseconds (msec), or QTc &gt; 480 msec in subjects
             with Bundle Branch Block. If a single QTc is abnormal, then the averaged QTc values of
             triplicate ECGs obtained (each separated by at least 5 min) will be utilized to
             determine eligibility.

          -  Active malignancy or carcinoma in situ in the past 5 years. There is an exception for
             basal cell carcinoma or cervical carcinoma in situ if they have had curative surgical
             treatment.

          -  Significant unstable acute illness or uncontrolled chronic disease other than PsA,
             which in the opinion of the investigator, would preclude the subject from study
             participation.

          -  Contraindication to MRI scanning (as assessed by local MRI safety questionnaire) which
             includes but not limited to: a. Intracranial aneurysm clips (except Sugita) or other
             metallic objects, b. History of intra-orbital metal fragments that have not been
             removed by a medical professional, c.Pacemakers or other implanted cardiac rhythm
             management devices and non-MR compatible heart valves, d.Inner ear implants, e.History
             of claustrophobia which may impact participation.

          -  Receiving treatment with anti-coagulant medications, including warfarin, heparin,
             thrombin inhibitors, and Factor Xa inhibitors, unless the subject is able to
             discontinue these medications one week prior to biopsies in the Pre-Treatment Phase
             and at one week prior to the Day 43 biopsies, unless local guidelines indicate a
             different timeframe, in which case local guidelines may be followed, taking into
             account the risk:benefit and the indication for use of those medications. The
             anticoagulants may be re-started 3 days after the biopsy, or according to local
             guidelines.

          -  Received treatment with the therapies listed below, within the prescribed timeframe.
             If in doubt, or the therapy is not listed, please consult with the medical monitor.
             Treatment with, cyclosporine, tacrolimus, hydroxychloroquine, azathioprine (28 days
             prior to Screening until Follow-up) apremilast or tofacitanib (At any time prior to
             Screening until Follow-up). Intravenous, intra-muscular or intra-articular
             glucocorticoids (28 days prior to screening until follow up). Topical psoriasis
             therapies (other than on face and genitals where topical therapy may continue during
             the study) (14 days prior to Screening until Follow-up).Emollients are allowed except
             on the day of study visits prior to assessments. Biologic therapies for the treatment
             of psoriasis, psoriatic arthritis or inflammatory arthritis including but not limited
             to anti-tumor necrosis factors biologics, etanercept, ustekinumab, secukinumab,
             rituximab, abatacept or tocilizumab (At any time prior to Screening until Follow-up).
             Alkylating agents (chlorambucil, cyclophosphamide) (At any time prior to Screening
             until Follow-up) Investigational biological and nonbiological immunomodulatory
             therapies (At any time prior to Screening until Follow-up). Psoralen long wave
             ultraviolet radiation treatment (28 days prior to Screening until Follow-up)
             Acitretin/Retinoids (28 days prior to Screening until Follow-up). Single treatment
             phototherapy (Ultraviolet B or self therapy with tanning bed or solarium) (14 days
             prior to Screening until Follow-up). Live vaccination Live vaccinations are not
             permitted within (28 days of first dose until 12 weeks after the last dose). If
             indicated, non-live vaccines (e.g. inactivated influenza vaccines) may be administered
             whilst receiving GSK3050002 based on an assessment of the benefit: risk (e.g. risk of
             Therapy Time period decreased responsiveness). Investigators are expected to follow
             local and/or national guidelines with respect to vaccinations, including against
             influenza and pneumococcus, in subjects with PsA.

          -  A history of drug and alcohol misuse that could interfere with participation in the
             trial according to the protocol, or in the opinion of the investigator impacts on the
             physical or mental wellbeing of the subject.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or medical
             monitor, contraindicates their participation. This include a history of severe drug
             allergies, including Type I hypersensitivity reactions to parenteral administration of
             human or murine proteins or monoclonal antibodies.

          -  Contraindication to gadolinium contrast agent in accordance with local guidelines.

          -  Presence of hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or
             positive hepatitis C antibody test result at screening or within 3 months prior to
             first dose of study treatment.

          -  Platelet count is &lt;100 x 10^9/mL or prothrombin time is above the laboratory upper
             limit of normal at screening.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Estimated GFR (Modification of Diet in Renal Disease [MDRD] calculation) of less than
             60 milliliters per minute (mL/min) per 1.73 squared meter /m^2 at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C-C chemokine receptor</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Chemokine (C-C motif) ligand 20</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>psoriasis</keyword>
  <keyword>Humanized Immunoglobulin G</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

